Vitae Pharmaceuticals Proposes Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Vitae Pharmaceuticals (VTAE) Sees 'Substantial' Costs for Developing VTP-43742, VTP-38543, VTP-36951
March 23, 2016 4:18 PM EDTVitae Pharmaceuticals (NASDAQ: VTAE) disclosed he following on Wednesday night:
ITEM 7.01. REGULATION FD DISCLOSURE.
On March 23, 2016, Vitae Pharmaceuticals, Inc. (Vitae) announced that Vitae currently anticipates that the net proceeds from the proposed public offering of its common stock,... More



